SCHEMBL1811166

SCHEMBL1811166

CC(Cc1ccc(Cl)cc1)NC(=O)c1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.55

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.55
PKM P14618 1/20 0.55
ACACB O00763 5/20 0.55
FPR2 P25090 1/20 0.52
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
TAS1R3 Q7RTX0 2/20 0.46
TAS1R1 Q7RTX1 2/20 0.46
TAS1R2 Q8TE23 2/20 0.46
BRD4 O60885 1/20 0.44
LMNA P02545 1/20 0.42
TSHR P16473 1/20 0.42
SLC6A2 P23975 1/20 0.41
SLC6A3 Q01959 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CNR1 P21554 1/20 0.41
CNR2 P34972 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1816088 0.83 ACACB (0.56) SMN1; SMN2PKMACACBFPR2RAB9A
SCHEMBL1812464 0.82 CNR1 (0.57) ACACBFPR2RAB9ANPC1LMNA
SCHEMBL9893002 0.78 ACACB (0.82) ACACB
SCHEMBL9891904 0.76 ACACB (0.61) ACACBFPR2RAB9ANPC1SLC6A2
SCHEMBL12204087 0.76 ACACB (0.57) ACACBFPR2RAB9ANPC1SLC6A2
SCHEMBL1815467 0.75 NPC1 (0.54) SMN1; SMN2PKMRAB9ANPC1TAS1R3
SCHEMBL1816209 0.75 ACACB (0.53) ACACBFPR2RAB9ANPC1MEN1
SCHEMBL12654827 0.75 ACACB (0.50) SMN1; SMN2ACACBFPR2RAB9ANPC1
SCHEMBL12621261 0.74 UTS2R (0.54) PKMACACBFPR2RAB9ANPC1
SCHEMBL4169995 0.74 PKM (0.70) SMN1; SMN2PKMTAS1R3TAS1R1TAS1R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 US claimed
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-09-29 US claimed
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-06-18 US claimed
EP-1960350-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2008-08-27 EP claimed
WO-2007060162-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2007-05-31 WO claimed
US-8314269-B2 N-(1-methyl-2phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2012-11-20 US disclosed
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-09-29 US disclosed
US-7951973-B2 N-(1-methyl-2Phenylethyl)benzamide derivatives BAYER CROPSCIENCE AG (DE) 2011-05-31 US disclosed
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives BAYER INTELLECTUAL PROPERTY GMBH (DE) 2009-06-18 US disclosed
EP-1960350-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2008-08-27 EP disclosed
WO-2007060162-A1 NEW N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES BAYER CROPSCIENCE SA (FR) 2007-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156682-A1 N-(1-Methyl-2Phenylethyl)Benzamide Derivatives CYP51A1, CYP1A2, CYP1A1 SMN1; SMN2 1807/4885PKM 690/4885ACACB 2344/4885
US-20110237678-A1 N-(1-METHYL-2PHENYLETHYL)BENZAMIDE DERIVATIVES CYP51A1, CYP1A2, CYP1A1 SMN1; SMN2 1859/4885PKM 662/4885ACACB 2371/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.